As Parents Clamor for a Treatment Touted for Autism, Doctors Hesitate to Prescribe It

Why It Matters

The episode illustrates how political messaging can rapidly reshape treatment markets, pressuring doctors to navigate unproven therapies and risking drug shortages for established uses.

Key Takeaways

• Leucovorin prescriptions rose 71% after federal endorsement.
• Parents formed large online groups seeking prescriptions.
• Major medical societies advise against routine use.
• Some private doctors charge up to $1,500 per visit.
• FDA limited approval to rare FOLR1 deficiency.

Pulse Analysis

The Trump administration’s high‑profile announcement thrust leucovorin into the autism spotlight, despite the drug’s longstanding use only for cerebral folate deficiency linked to the FOLR1 gene. Parents, desperate for breakthroughs, flocked to social media platforms, creating groups with tens of thousands of members sharing doctor referrals and dosing tips. This rapid information cascade amplified demand, leading to a 71% jump in prescriptions during the last quarter of 2025 and prompting concerns about the influence of political endorsement on medical practice.

Medical experts quickly cautioned that the evidence supporting leucovorin for autism is thin, citing small, retracted studies and a lack of long‑term safety data in children with neurodevelopmental disorders. The American Academy of Pediatrics and other professional bodies issued statements discouraging routine prescribing, while health systems such as Kaiser Permanente and Oregon Health & Science University barred its use pending further research. Nevertheless, a niche of private clinicians began offering the drug, often at steep out‑of‑pocket fees, creating a market where families must weigh unproven benefits against financial burden and potential side effects.

The controversy underscores broader challenges in healthcare: the erosion of clinician authority when public figures promote unverified treatments, the risk of drug shortages for oncology patients, and the diversion of resources from evidence‑based interventions like ABA therapy. Policymakers and insurers must balance rapid access to promising therapies with rigorous evaluation, ensuring that parental hope does not outpace scientific validation. Continued research into cerebral folate pathways may eventually clarify leucovorin’s role, but for now, the episode serves as a cautionary tale about the intersection of politics, social media, and medical decision‑making.